My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a ...

My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a hematologist. The hematologist would order a phlebotomy when his HCT was high. My ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best ...

panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection ...

Q: My friend says his uncle is being treated for a disease where he has too much blood and he gets "bloodletting’" every other day, like in the Middle Ages. Is there really such a thing, or is he ...

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. In this interview, Andrew Kuykendall, MD, ...

Two years after receiving FDA approval, Besremi is a preferred treatment option in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Besremi (ropeginterferon ...

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...

Patients with polycythemia vera (PV) who were resistant to or intolerant of hydroxyurea (HU) were randomized 1:1 to receive ruxolitinib 10 mg twice daily or best available therapy (BAT), which was ...

Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the potential of a disease-modifying therapy in polycythemia vera, treating high-risk vs low-risk patients, and emerging ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...